时间标签：数据日期 2026-11-01 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31–2026/11/01 ｜ 情报发生日期 2026-11-01
研究问题
In recent years, the diagnostic paradigm for AD has shifted from purely clinical assessment toward biomarker-based approaches.；Technological advances have enabled a transition from cerebrospinal fluid (CSF) to minimally invasive blood-based
方法
All statistical analyses and graph plotting were performed using SPSS 27 (IBM Corp., Armonk, NY, USA), R (version 4.5.0, R Foundation for Statistical Computing, Vienna, Austria), and GraphPad Prism 10 (GraphPad Software, San Diego, CA,…；Serum samples were collected to test thyroid function, syphilis, folate, homocysteine, vitamin B12, fasting glucose, glycated hemoglobin, and serum lipids to exclude alternative causes of cognitive decline.；Materials and methods Study participants A total of 275 participants were enrolled between February 2022 and October 2024 at the First Affiliated Hospital of Fujian Medical University.
核心结论
Combining serum NDEV mtDNA with Aβ40, p-Tau 217, GFAP, or APOE ε4 individually significantly improved diagnostic accuracy compared with single-indicator models.；In this study, we found serum NDEVs mtDNA levels were significantly lower in MCI than in CU controls, with a more pronounced decline in the AD group.；Literature reports have shown that a reduction in mtDNA copy number is significantly associated with a higher risk of progression from MCI to AD.；Meanwhile, our findings indicate that during the AD stage, NDEV mtDNA levels were associated with diabetic status and TG levels.；Conclusion In this study, we demonstrate for the first time that mtDNA levels in serum NDEVs are significantly reduced in patients with AD-MCI and in those with AD dementia, suggesting its potential as a non-invasive early-stage biomarker for MCI due to AD.
局限
Limitations This study also has some limitations, including the relatively small sample size in certain subgroups limits the statistical power and generalizability of our findings.；Future studies with larger, prospective cohorts, incorporating longitudinal measurements of serum NDEV mtDNA and comprehensive hematological indicators, are warranted to validate our findings and to further elucidate the role of…
对本项目的价值
高价值：血清神经元来源细胞外囊泡 mtDNA 作为 AD 所致 MCI 的无创生物标志物，属「线粒体 + 液体活检」交叉方向。 ｜ 价值分 4.0/5（★★★★☆）
全文来源
PubMed PMC JATS 全文（正文 39,918 字符，已过 DOI 逐字 + 题名指纹双重归属校验）
原文题录
- 英文标题：Serum neuron-derived extracellular vesicle mitochondrial DNA as a potential biomarker for mild cognitive impairment due to AD.
- 期刊与标识：Frontiers in aging neuroscience · PMID 42959066 · DOI 10.3389/fnagi.2026.1924123
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。